新型单克隆抗体By114有助于检测再生障碍性贫血中阵发性睡眠性血红蛋白尿克隆的早期出现。

The novel monoclonal antibody By114 helps detect the early emergence of a paroxysmal nocturnal hemoglobinuria clone in aplastic anemia.

作者信息

Tooze J A, Saso R, Marsh J C, Papadopoulos A, Pulford K, Gordon-Smith E C

机构信息

Department of Cellular and Molecular Sciences, St George's Hospital Medical School, London, UK.

出版信息

Exp Hematol. 1995 Dec;23(14):1484-91.

PMID:8542935

Abstract

The newly described monoclonal antibody By114 has been used with flow cytometry to investigate the status of the 90-kD glycosylphosphatidyl-inositol (GPI)-anchored component of CD66 (CD66c) on neutrophils from nine patients with paroxysmal nocturnal hemoglobinuria (PNH), seven with aplastic anemia/PNH, and 63 with aplastic anemia (AA) and a negative Ham's test. We have found that By114 is a sensitive indicator for recognizing patients with PNH and has helped delineate a group of nine patients with aplastic anemia and a negative Ham's test who have evidence of a larger PNH clone than indicated by other monoclonal antibodies (mAbs). By114 is a valuable marker for detecting the emergence of a PNH clone before the Ham's test becomes positive and is a more sensitive detector of deficient GPI-anchored proteins than other mAbs.

摘要

新描述的单克隆抗体By114已用于流式细胞术，以研究9例阵发性夜间血红蛋白尿（PNH）患者、7例再生障碍性贫血/PNH患者和63例再生障碍性贫血（AA）且Ham试验阴性患者中性粒细胞上CD66（CD66c）的90-kD糖基磷脂酰肌醇（GPI）锚定成分的状态。我们发现By114是识别PNH患者的敏感指标，并有助于确定一组9例再生障碍性贫血且Ham试验阴性的患者，这些患者有证据表明存在比其他单克隆抗体（mAb）所显示的更大的PNH克隆。By114是在Ham试验变为阳性之前检测PNH克隆出现的有价值标志物，并且是比其他mAb更敏感的GPI锚定蛋白缺陷检测剂。